These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26098287)

  • 1. Prognostic Significance of Intratumoral Metabolic Heterogeneity on 18F-FDG PET/CT in Pathological N0 Non-Small Cell Lung Cancer.
    Kim DH; Jung JH; Son SH; Kim CY; Hong CM; Oh JR; Jeong SY; Lee SW; Lee J; Ahn BC
    Clin Nucl Med; 2015 Sep; 40(9):708-14. PubMed ID: 26098287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of Intratumoral Metabolic Macroheterogeneity on 18F-FDG PET/CT and Its Prognostic Significance in Pathologic N0 Squamous Cell Lung Carcinoma.
    Kim DH; Jung JH; Son SH; Kim CY; Jeong SY; Lee SW; Lee J; Ahn BC
    Clin Nucl Med; 2016 Feb; 41(2):e70-5. PubMed ID: 26284762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y; Onishi H; Nambu A; Araki T
    Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography-derived metabolic parameters in surgically resected clinical-N0 nonsmall cell lung cancer.
    Aktas GE; Karamustafaoğlu YA; Balta C; Süt N; Sarikaya İ; Sarikaya A
    Nucl Med Commun; 2018 Nov; 39(11):995-1004. PubMed ID: 30188416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction for recurrence using F-18 FDG PET/CT in pathologic N0 lung adenocarcinoma after curative surgery.
    Kim DH; Son SH; Kim CY; Hong CM; Oh JR; Song BI; Kim HW; Jeong SY; Lee SW; Lee J; Ahn BC
    Ann Surg Oncol; 2014 Feb; 21(2):589-96. PubMed ID: 24046125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
    Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC
    Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.
    Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
    Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H
    Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of occult lymph node metastasis using SUV, volumetric parameters and intratumoral heterogeneity of the primary tumor in T1-2N0M0 lung cancer patients staged by PET/CT.
    Ouyang ML; Xia HW; Xu MM; Lin J; Wang LL; Zheng XW; Tang K
    Ann Nucl Med; 2019 Sep; 33(9):671-680. PubMed ID: 31190182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
    Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
    J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer.
    Sun M; Lu D; Li X; Wang J; Zhang L; Yang P; Yang Y; Shen J
    Cancer Med; 2024 Sep; 13(18):e70216. PubMed ID: 39302034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis.
    Liu J; Dong M; Sun X; Li W; Xing L; Yu J
    PLoS One; 2016; 11(1):e0146195. PubMed ID: 26727114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of
    Kim E; Wu HG; Keam B; Kim TM; Kim DW; Paeng JC; Kim HJ; Chang JH
    Clin Lung Cancer; 2019 Jan; 20(1):e9-e23. PubMed ID: 30266585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
    Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.